10.12.2020 • NewsAxensCargill

Axens, Cargill and IFPEN Link on Bio-Acrylic acid

French technology company Axens, its parent company IFP Energies nouvelles (IFPEN), and US food and agricultural giant Cargill are joining forces to further develop and scale bio-based acrylic acid.

The partners aim to commercialize lactic-to-acrylic-acid technology that Procter & Gamble has been developing in its laboratories and which it licensed to Cargill in May.

“By leveraging Cargill’s processing technology and IFPEN/Axens’ know-how in catalysis and scale up, we’re aiming to produce acrylic acid from renewable sources thereby reducing greenhouse gas emissions by more than 50 percent,” said Jill Zullo, vice president of bio-intermediates in Cargill’s bio-industrial business. She added that more than 6 million t of fossil-based acrylic acid will be produced this year.

Efforts will focus on the catalyst and process development needed to convert lactic acid into bio-based acrylic acid at scale. Acrylic acid is used in various applications, from hygiene products to household paints.

The companies will advance the technology according to staged milestones. Although it will be several years before it is ready to be deployed at commercial scale, they said test samples could be ready for potential customers sometime within the next 12 months. 

Author: Elaine Burridge, Freelance Journalist

Axens, IFP Energies nouvelles and Cargill are linking to further develop and...
Axens, IFP Energies nouvelles and Cargill are linking to further develop and scale bio-based acrylic acid. The partners aim to commercialize lactic-to-acrylic-acid technology that Procter & Gamble has been developing in its laboratories and which it licensed to Cargill in May. (c) PilMo Kang

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.